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Background and Purpose:Moyamoya disease has been classically described by the Asian
experience, yet clinical aspects of moyamoya phenomena in the United States remain
vastly undefined. The multifocal occlusive arterial disorder may be linked with numerous
conditions; however, later stages of this syndrome share common vascular pathophysiol-
ogy. This study is aimed at characterizing inpatient moyamoya cases in the United States
over a broad time span. Methods: A comprehensive analysis of the Nationwide Inpa-
tient Sample of the Healthcare Cost and Utilization Project (Releases 1–13, 1988–2004)
based on ICD-9-CM code 437.5 was performed. Annual percentages and trends analyses
were conducted for demographic variables, admission characteristics, co-morbidities, and
procedures. Result: 2247 admissions of moyamoya cases were analyzed from a wide
geographic distribution throughout the United States between 1988 and 2004. Age at
admission varied considerably (mean 29.6± 18.5 years), affecting women more frequently
thanmen (61.9%).Various racial groupswere identified (35.4%White, 19.7%AfricanAmer-
ican, 5.6% Hispanic, 8.3% Asian or Pacific Islander, 1.4% Native American). Admissions
were typically emergent (38.8%) or urgent (18.7%), although elective admissions occurred
(24.4%). Aside from moyamoya, sickle cell disease was diagnosed in 13.6%, ischemic
stroke in 20.7%, intracerebral hemorrhage in 7.4%, transient ischemic attack in 3.4%, and
subarachnoid hemorrhage in 3.1%. Cerebral angiography was performed in 24.9% while
extracranial–intracranial bypass was done in 8.4% of patients. Conclusion: Moyamoya in
the United States is a heterogeneous condition affecting individuals of all ages across a
diverse racial spectrum andwide geographic distribution. Further recognition of moyamoya
syndrome may facilitate ongoing research and future therapeutic approaches.
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INTRODUCTION
Moyamoya is a chronic cerebrovascular disease first described in
Japan in 1955 (Takeuchi and Shimizu, 1957). It is characterized by
the narrowing or occlusion of proximal cerebral arteries, in par-
ticularly the distal internal carotid, proximal middle, or anterior
cerebral arteries, which often leads to hypertrophy of lenticulos-
triate arteries and bypassing of the occlusive segment. Moyamoya
vasculopathy canbe categorized into the syndromeand thedisease.
Moyamoya syndrome includes the vasculopathic abnormalities in
addition to associated conditions, while moyamoya disease has no
other associated risk factors. Moyamoya refers specifically to the
angiographic findings (Scott and Smith, 2009).
The diagnostic criteria are as follows: (1) stenosis or occlu-
sion of the anterior cerebral, middle cerebral or internal carotid
arteries, (2) an abnormality of the vasculature surrounding these
arteries, and (3) the presence of bilateral disease seen angiograph-
ically. Diagnosis of moyamoya syndrome has been defined based
on cases that meet any two of these criteria. Conventional angiog-
raphy remains the gold-standard imaging technique for evalua-
tion of radiographic moyamoya; however, recent advances in MR
angiography are sufficient in specific cases (Burke et al., 2009).
While this disease has been reported worldwide, the estimates
of incidence in the United States have been limited (Goto and
Yonekawa, 1992; Edwards-Brown and Quets, 1997; Graham and
Matoba, 1997; Numaguchi et al., 1997; Uchino et al., 2005). Fur-
thermore, there is data that suggests differences in presentation in
the North American population compared with the Asian pop-
ulation (Bruno et al., 1988; Numaguchi et al., 1997; Chiu et al.,
1998; Cloft et al., 1999; Yilmaz et al., 2001; Hallemeier et al., 2006;
Mesiwala et al., 2008).
In this study, we report the inpatient characterization of the
moyamoya phenomenon in the United States between 1988 and
2004. Specifically, demographic data, admission diagnoses, and
associated procedures are analyzed.
MATERIALS AND METHODS
The National Inpatient Sample (NIS) database from 1988 to
2004 (Releases 1–13, 1988–2004) was searched for records with
a diagnosis of moyamoya using the International Classification
of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
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code 437.5. Annual percentages and trends analyses were con-
ducted for demographic variables, admission characteristics, co-
morbidities andprocedures using descriptive and frequency analy-
sis in SPSS (version 13.0). Admission type and disposition upon
discharge was analyzed in addition to the associated diagnoses and
procedures during each admission. Using the diagnosis-related
group (DRG) codes 001 (craniotomy age >17 except for trauma)
or 003 (craniotomy age <17) and the ICD-9-CM procedure code
39.28 (extracranial–intracranial vascular bypass), the incidence of
surgical revascularization was calculated (Uchino et al., 2005).
Additionally, we reviewed the number of computerized tomog-
raphy of the head (procedure code 87.03) andmagnetic resonance
imaging of the brain (procedure code 88.91). Secondary diag-
noses were also obtained: sickle cell (diagnosis code 282) and
neurofibromatosis (diagnosis code 23771 for specified and 23770
for unspecified). Race and ethnicity were determined based upon
the NIS database distinction: White, Hispanic, African American,
AsianAmerican (including Pacific Islander), andNativeAmerican.
RESULTS
We analyzed 2247 inpatient admissions with moyamoya between
1988 and 2004. In this cohort, the mean age of the patients was
29.6± 18.5, ranging from 0 to 101 years in age. Women were
admitted for moyamoya more often than men (61.9%, Figure 1).
Based upon the categories determined by theNIS database, the dis-
tribution of moyamoya disease among ethnicities during this time
period is as follows:Whites 35.4%,AfricanAmerican 19.7%,Asian
or Pacific Islanders 8.3%, Hispanics 5.6%, and Native Americans
1.4%.When comparing gender and ethnicity, all ethnicities except
African Americans displayed a female predominance (Figure 2).
The majority of admissions were for emergent care (38.8%),
followed by the elective admission type (24.4%) andurgent admis-
sions (18.7%). Inpatient stays were on average 7.75 days. In addi-
tion tomoyamoya, thepatients alsopresentedwithother diagnoses
upon admission.All of the patients were coded as having some sort
of cerebrovascular disease, while 20.7% of patients were admit-
ted with the diagnosis of an ischemic stroke (Goldstein, 1998).
Intracerebral hemorrhage occurred in 7.4%of cases, subarachnoid
hemorrhage in 3.1% or another unspecific intracranial hemor-
rhage in 0.6% of admissions. The diagnosis of a transient ischemic
attack (TIA) was present in 3.4% of admissions, while anemia was
coded in 13.5% of this cohort. Of note, sickle cell disease or trait
was noted in 13.6%of allmoyamoya cases,while only 51 caseswere
concomitantly diagnosed with neurofibromatosis. The principal
diagnosis in patients admitted for moyamoya follows a similar
order and included ischemic stroke (9.2%), anemia (7.6%), intrac-
erebral hemorrhage (5.5%), subarachnoid hemorrhage (2.4%),
and TIA (1.8%).
Cerebral angiography was the most common procedure per-
formed in these patients (24.9%). Surgical revascularization was
performed in 23.7% of patients. Specifically, craniotomies were
done on patients greater than 17 years of age in 10.1% of patients,
while patients between the ages of 0 and 17 received craniotomies
in 5.2% of the cases. Cerebral artery bypasses were also performed
in these patients (9.7%)with the extracranial–intracranial vascular
bypass being the most common (8.4%). Packed red cell transfu-
sions were indicated in 11.0% of this population. The principal
procedures followed a similar distribution: cerebral angiography
(13.1%), cerebrovascular bypass (7.9%), and packed red cell trans-
fusion (4.3%, Figure 3). Over the 17-year period, computerized
tomography of the head was only reported in 183 cases, whileMRI
was reported in 178 cases.
To determine the outcomes of patients after admission,we ana-
lyzed the inpatient deaths and discharge dispositions. There was
a 3.0% mortality rate during hospitalization, while the majority
of patients were routinely discharged (76.8%). Patients were also
discharged to short-term hospital facilities (4.6%), home health
care (4.3%), or other type of facility (9.4%).
DISCUSSION
Moyamoya in the US affects a broad spectrum of individuals from
diverse backgrounds and age groups. According to the NIS data-
base, thenumberof inpatientmoyamoya cases has been increasing;
however, this number is deceptive because the number of hospitals
sampled has also increased.Moyamoya is a lifelong process and has
been seen in patients ranging from newborn individuals to those
in their ninth decade. Since these patients are relatively stable,
this chronic disorder is often seen with other co-morbidities, and
patients are often subject to developing other pathologies.
In general, thereweremoremoyamoya admissions in the female
cohort (3:2 female-to-male), consistent with previous data sug-
gesting a 2:1 ratio (Scott et al., 2004; Baba et al., 2008). While
females generally had more admissions, there was a greater dif-
ference between female and male admissions between the ages of
19 and 55 years of age. Over the 17-year period based upon age
quartiles (0–18, 19–35, 36–55, greater than 55 years of age), female
admissions for moyamoya were greater in the 19–35 age group
(3:1 female-to-male), and 36–55 age group (2:1) compared with
the more extreme age groups (1:1). There was variability among
the years. For instance, males less than 18 years of age were admit-
ted for moyamoya more often than females less than 18 years of
age prior to 1998 at which point females in this age group were
more prevalent. Furthermore, there was a significant increase in
females between the ages of 36 and 55 years of age after 1994.
Based upon theNIS classification, theWhite ethnicity consisted
of the majority of moyamoya admissions. However, for patients
under 19 years of age, the African American ethnicity was the
majority (Whites 9.9%,African Americans 11.7%,Asian or Pacific
Islanders 2.4%,Hispanics 2.4%, andNativeAmericans 0.3% of the
total admission population). This finding may be due to an asso-
ciation between moyamoya and sickle cell disease (Pegelow, 2001;
Riebel et al., 2003; Gebreyohanns and Adams, 2004), as sickle cell
disease is more prevalent in the African American population.
Not all of the African American population has been concomi-
tantly diagnosed with sickle cell disease, as only 1.3% of the entire
population was diagnosed with a red cell blood disorder between
the ages of 0 and 17 years.
While this study does not have the ability to comment on med-
ical treatment, the percentage of bypasses coded increased over
time and peaking in the year 2001. In 1988, of the cases coded
none of the patients underwent a bypass, while in 2001, 21.5% of
patients with moyamoya underwent bypass. After 2001, there was
a decline in the percentage of patients who underwent bypass as
evidenced by only 10.3% of patients undergoing bypass in 2004.
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FIGURE 1 | Overall, there was a higher percentage of female relative to male hospital admissions for moyamoya; however, in general, there were
fewer males and females over 55 years of age who presented as hospital admissions. Of note after 1994, there was a decline in male hospital admissions
in patients less than 19 years of age.
FIGURE 2 | In the United States, there is a predominance of female-to-male admissions for moyamoya. Over this time period, there is a similar number
ofWhite and African American males, while moreWhite than African American females were admitted to the hospital with moyamoya during that time.
The incidence of cerebral angiography varied over time, ranging
from 13.9 to 47.1%; however, there was no particular trend in the
incidence of this procedure.
Moyamoya in the US may be distinct from Asian descriptions.
It is important to note that defining moyamoya is important
when analyzing the NIS database. The NIS does not distinguish
www.frontiersin.org July 2011 | Volume 2 | Article 43 | 3
Lee and Liebeskind Moyamoya in the United States
FIGURE 3 | Angiography remains the most common procedure associated with patients admitted for moyamoya, while there has been progressively
more cerebral artery bypasses from 1992–2004.
between moyamoya disease and moyamoya syndrome. It is likely
that the majority of the cases are likely moyamoya syndrome due
to the presence of various pathologies; however, this information
is unable to be ascertained based upon this data alone. Although
moyamoya may be rare, it is important to study these cases not
only for the care of these patients, but also becausemoyamoya syn-
dromemayprovide insight on the chronic development and role of
collaterals over time. Although surgical and nascent endovascular
techniques, such as stenting, may be utilized to revascularize these
individuals, the role and impact of these interventions needs to be
compared with natural history in the US. While it has not been
shown that indiscriminatemoyamoya screening is beneficial, there
has been a correlation with early screening for unilateral moy-
amoya onset and decreased stroke burden and improved clinical
outcome (Scott and Smith, 2009).
The moyamoya phenomenon is a varied disease, and this cod-
ing system does not differentiate between moyamoya disease and
moyamoya syndrome; however, it is more likely to actually be a
variant of the moyamoya phenomenon because it is such a rare
and specific condition. It is difficult to be certain that the same
patients are not being counted more than once due to a second
need for admission. As noted by Uchino et al. (2005) there may be
a selection and ascertainment bias as patients of Asian origin may
be given the diagnosis of moyamoya more commonly.
Due to the fact that this is a national database, this study is
restricted to the information inputted by the various hospitals
throughout the nation. It is only a study of inpatient hospitaliza-
tions and does not include outpatient data. Unfortunately, it does
not elucidate how these patientswere diagnosed. Typically, this dis-
ease process is diagnosed through angiography, and only 24.9% of
the patients reported here had this procedure. Thus, patient likely
were admitted with a prior diagnosis of moyamoya. An additional
possibility is that a particular patientmay have been admittedmul-
tiple times, suggesting a selection bias. Still, the numbers presented
here likely are underestimating the total number of patients across
the United States. The data gathered is approximates 20% of the
stratified sample of community hospitals across the United States.
During each year period, there are a different number of states
participating in the database, ranging from 8 states in 1988 to 37
states in 2004. Thus, even in the latest version not all states are rep-
resented. Furthermore, the sensitivity and specificity of the coding
system is unknown.However, this is themost comprehensive data-
base in the United States and is specific for moyamoya, providing
an objective measure. Moyamoya is a relatively rare phenomenon;
thus, it is unlikely that one would positively codemoyamoya, lead-
ing to relatively high specificity. This does suggest that the number
of cases reported in this study is an underestimate of the cases in
the United States.
CONCLUSION
Moyamoya in the United States remains a heterogeneous disease
process that affects a diverse population of individuals over a wide
geographic distribution. Continued cataloging of specific aspects
of moyamoya disease and syndrome may improve the character-
ization of this disease process and foster improved research and
therapeutic approaches.
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